US Bancorp’s Ligand Pharmaceuticals LGND Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q2
$517K Buy
1,636
+425
+35% +$100K ﹤0.01% 1548
2026
Q1
$242K Sell
1,211
-25
-2% -$4.95K ﹤0.01% 1914
2025
Q4
$234K Sell
1,236
-160
-11% -$30.7K ﹤0.01% 1947
2025
Q3
$247K Sell
1,396
-2,377
-63% -$353K ﹤0.01% 1891
2025
Q2
$429K Sell
3,773
-286
-7% -$30.6K ﹤0.01% 1589
2025
Q1
$427K Buy
4,059
+3,301
+435% +$373K ﹤0.01% 1574
2024
Q4
$81.2K Buy
758
+98
+15% +$11.1K ﹤0.01% 2497
2024
Q3
$66.1K Buy
660
+12
+2% +$1.21K ﹤0.01% 2596
2024
Q2
$54.6K Sell
648
-12
-2% -$955 ﹤0.01% 2620
2024
Q1
$48.2K Buy
660
+48
+8% +$3.54K ﹤0.01% 2721
2023
Q4
$43.7K Buy
612
+531
+656% +$31.3K ﹤0.01% 2739
2023
Q3
$4.85K Sell
81
-194
-71% -$12.8K ﹤0.01% 3442
2023
Q2
$19.8K Sell
275
-6
-2% -$450 ﹤0.01% 2983
2023
Q1
$20.7K Buy
281
+245
+681% +$17.4K ﹤0.01% 2973
2022
Q4
$2.4K Sell
36
-47
-57% -$3.06K ﹤0.01% 3727
2022
Q3
$5K Sell
83
-21
-20% -$1.23K ﹤0.01% 3596
2022
Q2
$6K Sell
104
-13
-11% -$738 ﹤0.01% 3529
2022
Q1
$8K Sell
117
-383
-77% -$27.8K ﹤0.01% 3460
2021
Q4
$48K Buy
500
+70
+16% +$6.47K ﹤0.01% 2682
2021
Q3
$38K Sell
430
-961
-69% -$74.3K ﹤0.01% 2782
2021
Q2
$114K Sell
1,391
-76
-5% -$6.32K ﹤0.01% 2241
2021
Q1
$140K Buy
1,467
+944
+180% +$89.2K ﹤0.01% 2084
2020
Q4
$32K Sell
523
-1,495
-74% -$85.2K ﹤0.01% 2703
2020
Q3
$120K Sell
2,018
-72
-3% -$4.91K ﹤0.01% 1999
2020
Q2
$146K Sell
2,090
-972
-32% -$61.6K ﹤0.01% 1920
2020
Q1
$139K Sell
3,062
-96
-3% -$5.44K ﹤0.01% 1863
2019
Q4
$206K Sell
3,158
-470
-13% -$31.4K ﹤0.01% 1804
2019
Q3
$225K Sell
3,628
-1,532
-30% -$96.2K ﹤0.01% 1746
2019
Q2
$367K Sell
5,160
-361
-7% -$26.6K ﹤0.01% 1555
2019
Q1
$433K Sell
5,521
-10,454
-65% -$792K ﹤0.01% 1446
2018
Q4
$1.35M Buy
15,975
+3,422
+27% +$365K ﹤0.01% 876
2018
Q3
$2.15M Sell
12,553
-5,288
-30% -$797K 0.01% 777
2018
Q2
$2.31M Buy
17,841
+1,468
+9% +$164K 0.01% 750
2018
Q1
$1.69M Sell
16,373
-1,225
-7% -$121K 0.01% 849
2017
Q4
$1.5M Buy
17,598
+3,923
+29% +$340K ﹤0.01% 910
2017
Q3
$1.16M Buy
13,675
+7,032
+106% +$557K ﹤0.01% 1004
2017
Q2
$503K Buy
6,643
+479
+8% +$33.5K ﹤0.01% 1405
2017
Q1
$407K Buy
6,164
+108
+2% +$7.11K ﹤0.01% 1474
2016
Q4
$384K Buy
6,056
+1,537
+34% +$97K ﹤0.01% 1491
2016
Q3
$287K Buy
4,519
+2,262
+100% +$166K ﹤0.01% 1597
2016
Q2
$168K Buy
2,257
+955
+73% +$70.9K ﹤0.01% 1773
2016
Q1
$87K Buy
1,302
+18
+1% +$1.09K ﹤0.01% 2088
2015
Q4
$87K Buy
1,284
+242
+23% +$14.9K ﹤0.01% 2147
2015
Q3
$55K Buy
1,042
+111
+12% +$6.74K ﹤0.01% 2405
2015
Q2
$59K Buy
931
+110
+13% +$6K ﹤0.01% 2451
2015
Q1
$40K Sell
821
-189
-19% -$7.24K ﹤0.01% 2651
2014
Q4
$34K Sell
1,010
-1,473
-59% -$47.9K ﹤0.01% 2704
2014
Q3
$73K Sell
2,483
-5,162
-68% -$171K ﹤0.01% 2275
2014
Q2
$297K Sell
7,645
-659
-8% -$26.7K ﹤0.01% 1618
2014
Q1
$348K Buy
8,304
+1,988
+31% +$82.9K ﹤0.01% 1500
2013
Q4
$206K Buy
6,316
+4,631
+275% +$151K ﹤0.01% 1708
2013
Q3
$45K Buy
+1,685
New +$47.4K ﹤0.01% 2376

Other funds holding LGND

US Bancorp's LGND Position: Q2 2026 in Review

US Bancorp increased its Ligand Pharmaceuticals (LGND) stake by 35% in Q2 2026, buying an estimated $100K and bringing the position to 1,636 shares worth $517K. The position accounts for ﹤0.01% of the portfolio, ranked #1548.

US Bancorp first reported a position in LGND in Q3 2013 and has held it in 52 quarters since. The position peaked at $2.31M in Q2 2018. 414 funds tracked by Wall St. Rank hold LGND as of Q2 2026.

  • US Bancorp held 1,636 shares of Ligand Pharmaceuticals worth $517K as of Q2 2026.
  • US Bancorp bought 425 Ligand Pharmaceuticals shares in Q2 2026, an estimated $100K.
  • Ligand Pharmaceuticals made up ﹤0.01% of US Bancorp's portfolio in Q2 2026, its #1548 holding.
  • US Bancorp first reported a position in Ligand Pharmaceuticals in Q3 2013 and has held it in 52 quarters since.
  • US Bancorp's Ligand Pharmaceuticals position peaked at $2.31M in Q2 2018.
  • 414 funds tracked by Wall St. Rank held Ligand Pharmaceuticals as of Q2 2026.

Based on US Bancorp's 13F filing for Q2 2026, filed 12 Aug 2026.